Publications: CPX-351
Manuscripts
Abstracts
Click abstract title to view poster
| |
Liposome accumulation within leukemia engrafted bone marrow is significantly enhanced when the formulation contains cytarabine plus daunorubicin | Johnstone et al, American Society of Cancer Research (AACR) Annual Meeting 2010, Abstract #5534 |
| |
|
| |
Phase IIb Randomized Study of CPX-351 vs. Conventional Cytarabine + Daunorubicin
in Newly Diagnosed AML Patients Aged 60-75: Safety Report | Lancet et al, American Society of Hematology (ASH) Annual Meeting 2009, Abstract #1033 |
| |
|
| |
Improved Selectivity against Acute Myeloid Leukemia (AML) Blasts Over Normal Hematopoietic
Progenitors for Cytarabine:Daunorubicin Delivered as CPX-351 Liposome Injection | Kim et al, American Society of Hematology (ASH) Annual Meeting 2009, Abstract #2071 |
| |
|
| |
Leukemia Cell-Selective Uptake of Cytarabine (Cyt) and Daunorubicin (Daun) Mediated by CPX-351 Liposome Injection in the Bone Marrow Compartment | Harasym et al, European Hematology Association 14th Congress 2009, Abstract #383 |
| |
|
| |
Pharmacology of CPX-351: A Nano-scale Liposomal Fixed Molar Ratio Cytarabine-Daunorubicin for Patients with Advanced Leukemia | Feldman et al, European Hematology Association 14th Congress 2009, Abstract #1398 |
| |
|
| |
CPX-351, a liposome formulation containing a synergistic 5:1 molar ratio of cytarabine (Cyt) and daunorubicin (Daun), exhibitis improved efficacy against human leukemia xenografts when administered at intermediate frequency in consolidation treatment | Tardi et al, American Association for Cancer Research (AACR) Annual Meeting 2009, Abstract #4568 |
| |
|
| |
Phase 1 study of a liposomal carrier (CPX-351) containing a synergistic, fixed molar ratio of cytarabine
(Ara-C) and daunorubicin (DNR) in advanced leukemias | Feldman et al, American Society of Hematology (ASH) Annual Meeting 2008, Abstract #2984 |
| |
|
| |
Synergistic cytarabine:daunorubicin ratios delivered by CPX-351 to human leukemia xenografts is associated with liposome-mediated bone marrow drug accumulation, intracellular delivery of encapsulated agents to leukemia cells, and increased efficacy | Mayer et al, American Society of Hematology (ASH) Annual Meeting 2008, Abstract #942 |
| |
|
| |
Phase I Study of a Liposomal Carrier (CPX-351) Containing an Optimized, Synergistic, Fixed Molar Ratio of Cytarabine and Daunorubicin in Advanced Leukemias and Myelodysplastic Syndromes | Feldman et al, American Society of Hematology (ASH) Annual Meeting 2007, Abstract #900 |
| |
Cytarabine:daunorubicin combined inside lipsomes at a fixed synergistic ratio leads to potent therapeutic activity against a range of preclinical leukemia models | Johnstone et al, American Association for Cancer Research (AACR) Annual Meeting 2006, Abstract #5310 |
| |
Synergistic antitumor activity observed for a fixed ratio liposome formulation of cytarabine:daunorubicin against preclinical leukemia models | Johnstone et al, American Association for Cancer Research (AACR) Annual Meeting 2005, Abstract #1405 |
|
